Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Business & Regulation Standards & Regulation, Quality & Compliance

Five Steps You Won’t Want to Miss When Filing an IND

sponsored by Regis

The FDA requires drug makers to submit an Investigational New Drug (IND) application when shipping an unapproved product across state lines for human clinical trials, as well as for approved products being studied for not-yet-approved uses. For a New Chemical Entity, filing an IND is the first step towards a first-in-human Phase I clinical trial. Active Pharmaceutical Ingredients targeting a new therapeutic indication require an IND filing as well.

What are the most important things to consider when filing an IND? This infographic, sponsored by Regis, sets out the five key steps to success.

Click Here to Download

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine